Pharma Nord SRL
20.6 FTEPharma Nord reported total assets of €1.77m at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Jun 2026), with 20.6 full-time equivalents.
The score of Pharma Nord shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -79 % Total assets +10 % Headcount (avg FTE) +13 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma Nord's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jun 2026
- Year ended 31 Dec 2024filed on 30 Jun 2025
- Year ended 31 Dec 2023filed on 09 Jul 2024
- Year ended 31 Dec 2022filed on 19 Jun 2023
- Year ended 31 Dec 2021filed on 23 Jun 2022
Pharma Nord's financial analysis
- Solvency1.2%sector median: 46.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma Nord
Pharma Nord's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0459.551.554
- VAT number
- BE0459551554
- Peppol
- Registered · 0208:0459551554 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Dec 1996
- Registered office
- 1930 Zaventem
- Size
- Small · 20.6 FTE
- Latest accounts
- 2025 · filed on 29 Jun 2026
- Activity
- Activities of advertising agencies (NACE 73110)
Pharma Nord (SRL) has been based in Zaventem since 1996, active in: activities of advertising agencies. For 2025, it reports a net profit of 77,582 € and equity of 20,513 €; its revenue is not published. With 20.6 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 1.2%, below the median of its sector (46.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharma Nord
Companies in the same business, of comparable size and area, outside its group.
- June20 Activities of advertising agencies Ghent · balance sheet €1.70m
- Minale Design Strategy Activities of advertising agencies Ixelles · balance sheet €1.70m
- Magic Image Activities of advertising agencies Forest · balance sheet €3.67m
- MEYE Activities of advertising agencies Antwerp · balance sheet €1.49m
- Mission-Systole Activities of advertising agencies Uccle · balance sheet 619,767 €
- eFluenz Activities of advertising agencies Brussels · balance sheet €1.19m
- Oona_19 Activities of advertising agencies Antwerp · balance sheet €6.04m
- Cafe Grafiek Activities of advertising agencies Ypres · balance sheet 509,167 €
Frequently asked questions about Pharma Nord
What is the revenue of Pharma Nord?
Pharma Nord files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma Nord?
In Belgium, the VAT number is the company number prefixed with BE: BE0459551554 for Pharma Nord, if the company is VAT-registered. Its company number (CBE) is 0459.551.554.
Where is the registered office of Pharma Nord?
According to the CBE register, the registered office of Pharma Nord is in 1930 Zaventem.
What is the equity of Pharma Nord?
At the close of the 2025 financial year, the equity of Pharma Nord amounts to 20,513 €, a solvency of 1.2% of total assets.
How many people work at Pharma Nord?
20.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharma Nord?
The register lists 2 active mandates at Pharma Nord. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma Nord
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →